P. Schaeffer

发表

Nonproteolytic activation of the thrombin receptor promotes human umbilical vein endothelial cell growth but not intracellular CA2+, prostacyclin, or permeability.

J. Herbert, P. Schaeffer, E. Riera, 1997, Biochemical pharmacology.

Detection of bradykinin B1 receptors in rat aortic smooth muscle cells.

J. Herbert, P. Savi, P. Schaeffer, 2001, Biochemical pharmacology.

K+ efflux pathways and neurotransmitter release associated to hippocampal ischemia: effects of glucose and of K+ channel blockers

M. Lazdunski, P. Schaeffer, 1991, Brain Research.

JPET # 59873 1 Effects of SanOrg 123781 A , a synthetic heparin mimetic , in a mouse model of electrically induced carotid artery injury : synergism with the antiplatelet agent clopidogrel

N. Roome, J. Herbert, R. Masson, 2003 .

Factor Xa Activates Endothelial Cells by a Receptor Cascade Between EPR-1 and PAR-2

J. Herbert, F. Bono, J. Guillemot, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice

B. Staels, F. Bono, R. Paumelle, 2009, Arteriosclerosis, thrombosis, and vascular biology.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

A. Klein-Szanto, P. Casellas, P. Dobrzanski, 2003, Cancer research.

Activation of human vascular endothelial cells by factor Xa: effect of specific inhibitors.

J. Herbert, J. Hérault, F. Bono, 1999, Biochemical pharmacology.

Effect of SR 33805 on arterial smooth muscle cell proliferation and neointima formation following vascular injury.

J. Herbert, P. Chatelain, P. Schaeffer, 1995, European journal of pharmacology.

Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities

F. Barbe, M. Pelat, J. Guillon, 2020, The Journal of Pharmacology and Experimental Therapeutics.

The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways

P. Hellings, S. Pollefeyt, D. Collen, 2002, The Journal of experimental medicine.

Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice.

J. Herbert, L. Millet, M. Arnone, 2006, European journal of pharmacology.

Angiotensin AT1 Receptor Antagonist Irbesartan Decreases Lesion Size, Chemokine Expression, and Macrophage Accumulation in Apolipoprotein E‐Deficient Mice

J. Herbert, B. Staels, D. Nisato, 2001, Journal of cardiovascular pharmacology.

Tumor Vasculature Is Regulated by FGF/FGFR Signaling‐Mediated Angiogenesis and Bone Marrow‐Derived Cell Recruitment: This Mechanism Is Inhibited by SSR128129E, the First Allosteric Antagonist of FGFRs

J. Herbert, F. Géronimi, F. Bono, 2015, Journal of cellular physiology.

SSR182289A enhances thrombolysis induced by fibrinolytic agents in rabbit models of venous and arterial thrombosis

J. Herbert, L. Millet, J. Lorrain, 2004, Journal of thrombosis and haemostasis : JTH.

Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro.

J. Herbert, D. Nisato, P. Chatelain, 1994, European journal of pharmacology.

Antithrombotic Properties of SSR182289A, a New, Orally Active Thrombin Inhibitor

J. Herbert, L. Millet, J. Lorrain, 2003, Journal of Pharmacology and Experimental Therapeutics.

P2Y4 nucleotide receptor: a novel actor in post-natal cardiac development

J. Balligand, C. Dessy, C. Gachet, 2012, Angiogenesis.

SAR131675, a Potent and Selective VEGFR-3–TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities

F. Bono, P. Savi, I. Blanc, 2012, Molecular Cancer Therapeutics.

Therapeutic Discovery SAR 131675 , a Potent and Selective VEGFR-3 – TK Inhibitor with Antilymphangiogenic , Antitumoral , and Antimetastatic Activities

F. Bono, P. Savi, I. Blanc, 2012 .

Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways.

S. Pollefeyt, D. Collen, J. Herbert, 2002, Gastroenterology.

Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy

J. Herbert, L. Millet, J. Hérault, 2008, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetics of New Synthetic Heparin Mimetics

J. Herbert, J. Hérault, F. Bono, 2002, Thrombosis and Haemostasis.

Life-Threatening Thrombosis in Mice With Targeted Arg48-to-Cys Mutation of the Heparin-Binding Domain of Antithrombin

P. Carmeliet, L. Moons, D. Collen, 2003, Circulation research.

Heparin-Binding Domain of Antithrombin Life-Threatening Thrombosis in Mice With Targeted Arg 48-to-Cys Mutation of the Print

P. Carmeliet, L. Moons, D. Collen, 2003 .

Interactions of calmodulin antagonists with calcium antagonists binding sites.

C. Lugnier, P. Schaeffer, J. Stoclet, 1991, European journal of pharmacology.

Characterization of cardiac angiotensin AT1 receptors by [3H]SR 47436.

P. Chatelain, P. Schaeffer, C. Cazaubon, 1993, European journal of pharmacology.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.

P. Soubrié, D. Gully, R. Boigegrain, 1999, The Journal of pharmacology and experimental therapeutics.

Effects of SanOrg123781A, a synthetic heparin mimetic, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel.

J. Herbert, R. Masson, J. Lorrain, 2003 .

Effects of bepridil and of its quaternary derivative on rat tail artery.

P. Schaeffer, J. Stoclet, J. Baissat, 1986, European journal of pharmacology.

SR123781A, a Synthetic Heparin Mimetic

J. Herbert, J. Hérault, P. Savi, 2001, Thrombosis and Haemostasis.

SSR182289A, a selective and potent orally active thrombin inhibitor.

J. Herbert, Z. Bocskei, J. Lorrain, 2004, Bioorganic & medicinal chemistry.

SR142948A is a potent antagonist of the cardiovascular effects of neurotensin.

J. Herbert, P. Schaeffer, A. Bernat, 1998, Journal of cardiovascular pharmacology.

Neurotensin induces the release of prostacyclin from human umbilical vein endothelial cells in vitro and increases plasma prostacyclin levels in the rat.

J. Herbert, P. Schaeffer, A. Bernat, 1997, European journal of pharmacology.

Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo.

J. Herbert, J. Hérault, F. Bono, 1998, The Journal of clinical investigation.

Effects of SanOrg123781A, a Synthetic Hexadecasaccharide, in a Mouse Model of Electrically Induced Carotid Artery Injury: Synergism with the Antiplatelet Agent Clopidogrel

N. Roome, J. Herbert, R. Masson, 2004, Journal of Pharmacology and Experimental Therapeutics.

Calmodulin and its role in intracellular calcium regulation

C. Lugnier, M. Kilhoffer, P. Schaeffer, 1987, Progress in Neurobiology.

Amiodarone is a potent calmodulin antagonist

C. Lugnier, P. Schaeffer, P. Nokin, 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

Comparative effects of calmodulin inhibitors on calmodulin's hydrophobic sites and on the activation of cyclic nucleotide phosphodiesterase by calmodulin.

A. Follenius-Wund, P. Schaeffer, D. Gérard, 1987, Biochemical pharmacology.

Lesion Progression in apoE-Deficient Mice: Implication of Chemokines and Effect of the AT1 Angiotensin II Receptor Antagonist Irbesartan

J. Herbert, D. Hum, B. Staels, 2004, Journal of cardiovascular pharmacology.

Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.

Jie Zhang, Harald Schwalbe, Francesco Luigi Gervasio, 2013, Cancer cell.

Human Umbilical Vein Endothelial Cells Express High Affinity Neurotensin Receptors Coupled to Intracellular Calcium Release (*)

J. Herbert, P. Savi, P. Schaeffer, 1995, The Journal of Biological Chemistry.

Antiplatelet and Antithrombotic Activity of SL65.0472, a Mixed 5-HT1B/5-HT2A Receptor Antagonist

J. Herbert, P. Savi, P. Janiak, 2001, Thrombosis and Haemostasis.

Comparison of myocardial preservation techniques for aortocoronary bypass surgery.

J. Siegel, A. Vladutiu, P. Schaeffer, 1977, The Journal of surgical research.

Human umbilical vein endothelial cells express high affinity receptors for factor Xa

J. Herbert, F. Bono, J. Lormeau, 1997, Journal of cellular physiology.

Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes

I. Castan-Laurell, C. Dray, O. Kunduzova, 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Coagulation factor Xa induces endothelium-dependent relaxations in rat aorta.

J. Herbert, F. Bono, P. Schaeffer, 1997, Circulation research.

Dissociation between the excitatory and "excitotoxic" effects of quinolinic acid analogs on the striatal cholinergic interneuron.

J. Coyle, J. Lehmann, J. Ferkany, 1985, The Journal of pharmacology and experimental therapeutics.

Double-blind trial of venlafaxine and paroxetine for treatment-resistant depression

P. Boyer, M. Poirier, P. Schaeffer, 1998, European Neuropsychopharmacology.

CCK‐JMV‐180 acts as an antagonist of the CCKA receptor in the human IMR‐32 neuroblastoma cell line

J. Herbert, P. Schaeffer, V. Prabonnaud, 1994, FEBS letters.

Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy.

P. Carmeliet, S. Goff, D. Collen, 2005, The Journal of clinical investigation.

Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.

J. Herbert, G. Le Fur, P. Schaeffer, 1995, The American journal of physiology.

Peelfit: An Integrated Computer Program for Pharmacokinetic Analysis

P. Schaeffer, A. Stamm, P. Seth, 1987 .

P2Y4 nucleotide receptor: a novel actor in post-natal cardiac development

J. Balligand, C. Dessy, C. Gachet, 2012, Angiogenesis.

A New Synthetic FGF Receptor Antagonist Inhibits Arteriosclerosis in a Mouse Vein Graft Model and Atherosclerosis in Apolipoprotein E-Deficient Mice

F. Bono, P. Schaeffer, A. Nestor, 2013, PloS one.

Experimental Studies on Guanosine 3’,5’-Cyclic Monophosphate Levels and Airway Responsiveness of the Novel Phosphodiesterase Type 5 Inhibitor

J. Herbert, M. Pascal, P. Schaeffer, 1999, Arzneimittelforschung.

Interaction of calmodulin and calcium antagonists with [3H]diltiazem and [3H]nitrendipine binding sites.

C. Lugnier, P. Schaeffer, J. Stoclet, 1988, Journal of cardiovascular pharmacology.

[Multicenter double-blind study comparing the efficacy and tolerance of paroxetine and clomipramine in reactive depression in the elderly patient].

P. Schaeffer, Y. Pélicier, 1993, L'Encephale.

Characterisation of the effects of SR146131, a novel non-peptide CCK(1) receptor agonist, on IMR-32 human neuroblastoma cells.

J. Herbert, P. Schaeffer, M. Laplace, 2000, European journal of pharmacology.

Preclinical evidence that SSR128129E--a novel small-molecule multi-fibroblast growth factor receptor blocker--radiosensitises human glioblastoma.

C. Toulas, J. Bonnet, F. Bono, 2014, European journal of cancer.

Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice

B. Staels, F. Bono, R. Paumelle, 2009, Arteriosclerosis, thrombosis, and vascular biology.